Snehal Patel

Executive Vice President and Chief Technical Officer
Sana Biotechnology



​

Snehal Patel is the Chief Technical Officer at Sana Biotechnology.  He has oversight of all technical operations including, Process/Analytical Development, Manufacturing, Supply Chain, Environmental Health & Safety, CMC Regulatory, and Technical Quality for Cell and Gene Therapy.  Snehal has a breadth of knowledge and experience in leading programs from pre-clinical, phase 1, pivotal and through commercial launch in Cell Therapy and Biologics.  He has had leading roles in Global Manufacturing, Technology, Supply Chain, and Quality Assurance in Biologics, Small Molecules, and most recently in Cell & Gene Therapy.
 
Prior to Sana Biotechnology, Snehal was the Global Head for Cell Therapy Manufacturing at Bristol Myers Squibb (BMS). He led the growing global manufacturing network to produce Clinical and Commercial Cell Therapy Products, including two cell therapies commercially launched in 2021 by BMS. Prior to this role he served as General Manager & Site Head for Cell Therapy Manufacturing in Bothell, Washington for Juno Therapeutics.  Prior to Juno, Snehal worked at Genentech/Roche for 18 years, holding a variety of different roles with increasing responsibility, including Head of Global External Drug Product Manufacturing, Head of Drug Product Operations, and Head of Quality Operations.

​

Speech title & Synopsis

Overcoming Allogenic Immune Rejection

Overcoming allogenic immune rejection has been a key limitation in transplant and cellular medicine.  In this presentation I will briefly describe Sana’s Hypo Immune Platform (HIP) technology and Sana is advancing toward a cure for Type 1 Diabetes.